Mother-infant transfer of anti-human papillomavirus (HPV) antibodies following vaccination with the quadrivalent HPV (type 6/11/16/18) virus-like particle vaccine

Clinical and Vaccine Immunology

Volumn 19, Issue 6, 2012, Pages 881-885

  Matys, Katie ^a,e   Mallary, Sara ^b   Bautista, Oliver ^b   Vuocolo, Scott ^b   Manalastas, Ricardo ^c   Pitisuttithum, Punee ^d   Saah, Alfred ^b  

^a Wayne Clinical Assays   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c PHILIPPINE GENERAL HOSPITAL   (Philippines)

^d MAHIDOL UNIVERSITY   (Thailand)

^e PPD Vaccine and Biologics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; PLACEBO; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE; WART VIRUS VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; INFANT; MAJOR CLINICAL STUDY; MATERNAL BLOOD; PLACENTAL TRANSFER; PRIORITY JOURNAL; UMBILICAL CORD BLOOD; VACCINATION; VIRUS TYPING;

ADULT; ANTIBODIES, VIRAL; FEMALE; FETAL BLOOD; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNOGLOBULIN G; INFANT; INFANT, NEWBORN; MIDDLE AGED; PAPILLOMAVIRUS VACCINES; PHILIPPINES; PREGNANCY; THAILAND; VACCINES, VIROSOME;

EID: 84861757306     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00002-12     Document Type: Article

References (31)

1. Carter JJ, et al. 2006. Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J. Virol. 80:4664-4672.
2. Castellsague X, et al. 2011. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br. J. Cancer 105:28-37.
3. Christensen ND, Kreider JW. 1990. Antibody-mediated neutralization in vivo of infectious papillomaviruses. J. Virol. 64:3151-3156. (Pubitemid 20219515)
4. Christensen ND, Kreider JW, Cladel NM, Galloway DA. 1990. Immunological cross-reactivity to laboratory-produced HPV-11 virions of polysera raised against bacterially derived fusion proteins and synthetic peptides of HPV-6b and HPV-16 capsid proteins. Virology 175:1-9. (Pubitemid 20093055)
5. Christensen ND, Kreider JW, Cladel NM, Patrick SD, Welsh PA. 1990. Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11. J. Virol. 64:5678-5681. (Pubitemid 20364570)
6. Christensen ND, Kreider JW, Shah KV, Rando RF. 1992. Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions. J. Gen. Virol. 73:1261-1267.
7. Christensen ND, Reed CA, Cladel NM, Hall K, Leiserowitz S. 1996. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to typespecific epitopes on HPV-6. Virology 224:477-486. (Pubitemid 26364495)
8. Culp TD, Spatz CM, Reed CA, Christensen ND. 2007. Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles. Virology 361:435-446. (Pubitemid 46574856)
9. D'Angio CT. 2007. Active immunization of premature and low birth-weight infants: a review of immunogenicity, efficacy, and tolerability. Paediatr. Drugs 9:17-32.
10. Derkay CS. 1995. Task force on recurrent respiratory papillomas. A preliminary report. Arch. Otolaryngol. Head Neck Surg. 121:1386-1391.
11. Dias D, et al. 2005. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomavirus 6, 11, 16 and 18. Clin. Diagn. Lab. Immunol. 12:959-969.
12. FUTURE II Study Group. 2007. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356:1915-1927.
13. Garland SM, et al. 2007. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 356:1928-1943. (Pubitemid 46740303)
14. Giroglou T, et al. 2001. Immunological analyses of human papillomavirus capsids. Vaccine 19:1783-1793. (Pubitemid 32175741)
15. Giuliano AR, et al. 2011. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N. Engl. J. Med. 364:401-411.
16. Glick C, Feldman S, Norris MR, Butler J. 1998. Measles, mumps, and rubella serology in premature infants weighing less than 1,000 grams. South. Med. J. 91:159-160.
17. Hamilton RG. 1990. Engineered human antibodies as immunologic quality control reagents. Ann. Biol. Clin. (Paris) 48:473-477. (Pubitemid 20356873)
18. Heim K, et al. 2007. Type-specific antiviral antibodies to genital human papillomavirus types in mothers and newborns. Reprod. Sci. 14:806-814. (Pubitemid 351903566)
19. Kashima HK, Mounts P, Shah K. 1996. Recurrent respiratory papillomatosis. Obstet. Gynecol. Clin. North Am. 23:699-706. (Pubitemid 26282358)
20. Langkamp DL, Davis JP. 1996. Increased risk of reported pertussis and hospitalization associated with pertussis in low birth weight children. J. Pediatr. 128:654-659. (Pubitemid 26137724)
21. Linder N, et al. 1997. Placental transfer of hepatitis A antibodies in full term and preterm infants. Pediatr. Infect. Dis. J. 16:245-247. (Pubitemid 27078798)
22. Linder N, et al. 1999. Placental transfer of maternal rubella antibodies to full-term and preterm infants. Infection 27:203-207. (Pubitemid 29257746)
23. Linder N, et al. 2000. Placental transfer and decay of varicella-zoster virus antibodies in preterm infants. J. Pediatr. 137:85-89. (Pubitemid 30470928)
24. Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. 1996. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am. J. Reprod. Immunol. 36:248-255. (Pubitemid 26383975)
25. Munoz N, et al. 2009. Safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women between 24 and 45 years of age: a randomized, double-blind trial. Lancet 373:1949-1957.
26. Olsson S-E, et al. 2007. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like-particle vaccine. Vaccine 25:4931-4939. (Pubitemid 46843434)
27. Opalka D, et al. 2003. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16 and 18 by a multiplexed luminex assay. Clin. Diagn. Lab. Immunol. 10:108-115. (Pubitemid 36133838)
28. Opalka D, et al. 2010. Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin. Vaccine Immunol. 17:818-827.
29. Ryding J, Dahlberg L, Wallen-Ohman M, Dillner J. 2007. Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles. J. Gen. Virol. 88:792-802. (Pubitemid 46359548)
30. Sadeghi K, et al. 2007. Immaturity of infection control in preterm and term newborns is associated with impaired toll-like receptor signaling. J. Infect. Dis. 195:296-302. (Pubitemid 46080062)
31. Syrjanen S. 2005. Human papillomavirus (HPV) in head and neck cancer. J. Clin. Virol. 32:S59-S66. (Pubitemid 40332590)